- Home
- ACRS vs ASRT Comparison
ACRS vs ASRT Comparison
Compare ACRS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ASRT
- Stock Information
- Founded
- ACRS 2012
- ASRT 1995
- Country
- ACRS United States
- ASRT United States
- Employees
- ACRS N/A
- ASRT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- ASRT Health Care
- Exchange
- ACRS Nasdaq
- ASRT Nasdaq
- Market Cap
- ACRS 132.0M
- ASRT 105.8M
- IPO Year
- ACRS 2015
- ASRT 1997
- Fundamental
- Price
- ACRS $4.32
- ASRT $0.97
- Analyst Decision
- ACRS Buy
- ASRT Strong Buy
- Analyst Count
- ACRS 6
- ASRT 4
- Target Price
- ACRS $7.20
- ASRT $3.19
- AVG Volume (30 Days)
- ACRS 6.0M
- ASRT 909.6K
- Earning Date
- ACRS 11-06-2024
- ASRT 11-11-2024
- Dividend Yield
- ACRS N/A
- ASRT N/A
- EPS Growth
- ACRS N/A
- ASRT N/A
- EPS
- ACRS N/A
- ASRT N/A
- Revenue
- ACRS $27,079,000.00
- ASRT $125,763,000.00
- Revenue This Year
- ACRS N/A
- ASRT N/A
- Revenue Next Year
- ACRS N/A
- ASRT $4.68
- P/E Ratio
- ACRS N/A
- ASRT N/A
- Revenue Growth
- ACRS 26.35
- ASRT N/A
- 52 Week Low
- ACRS $0.77
- ASRT $0.73
- 52 Week High
- ACRS $5.17
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- ASRT 48.07
- Support Level
- ACRS $3.67
- ASRT $0.78
- Resistance Level
- ACRS $5.17
- ASRT $1.08
- Average True Range (ATR)
- ACRS 0.47
- ASRT 0.09
- MACD
- ACRS 0.20
- ASRT 0.01
- Stochastic Oscillator
- ACRS 72.93
- ASRT 61.90
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.